OncoC4, Inc.
PrivateLast Round
Series B
Oct 2, 2025
Est. Valuation
$660M
Total Funding Raised
$341M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
OncoC4, Inc. operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Series B round in October 2025.
OncoC4, Inc. is a clinical-stage biotechnology company that discovers and develops novel biologics for the treatment of cancer and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoC4, Inc. Comparables
Compare OncoC4, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pheast Therapeutics | 81% | |
| Xilio Therapeutics | 81% | |
| Instil Bio | 81% |
For institutional investors. Book with your work email.
OncoC4, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 2, 2025 | ||||
| Strategic | Mar 20, 2023 | ||||
| Convertible Debt | Apr 1, 2022 | ||||
| Series A | Dec 1, 2020 | ||||
| Grant | Sep 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OncoC4, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gobi Partners | Series B |
| HM Capital | Series B |
| Bencao Capital | Series A, Series B |
| Kaitai Capital | Series A, Series B |
| National Institutes of Health (NIH) | Grant |
| Greater Bay Area Homeland | Series B |
| HM Venture Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Presented Phase 1/2 trial data at SITC 2026.
- Nov 6, 2026
Phase 1/2 data for cesalatamig in lung cancer shows encouraging results.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
OncoC4, Inc. attends SITC 2026 in Arizona on Nov 6th '26 and reports encouraging Phase 1/2 results for cesalatamig monotherapy in previously treated non-small cell lung cancer.
- hiresNov 2, 2026
OncoC4, Inc. appoints Dr. Dan Janiak as Chief Business Officer in Maryland on Nov 2nd '26, following his role as Executive Director of Business Development at AstraZeneca.
- hiresNov 2, 2026
OncoC4, Inc. welcomes Dan Janiak as Chief Business Officer, bringing more than 15 years of experience in biotechnology strategy, business development, venture investing, and company formation.
- attends_eventOct 29, 2026
OncoC4, Inc. presents a late-breaking abstract on cesalatamig in patients with PD-(L)1-resistant or refractory non-small cell lung cancer at the 41st Annual Meeting in Arizona on Nov 7th '26.
- is_developingOct 29, 2026
OncoC4, Inc. co-develops gotistobart (BNT316/ONC-392) with BioNTech as a tumor microenvironment-selective Treg depletion candidate targeting CTLA-4, including in an ongoing pivotal clinical trial for squamous non-small cell lung cancer.
For institutional investors. Book with your work email.
OncoC4, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OncoC4, Inc.'s valuation, stock price, and market status.
Is OncoC4, Inc. a public or private company?
OncoC4, Inc. is a private company.
What is the current stock price of OncoC4, Inc.?
OncoC4, Inc. is a private company, so its shares have no public market price. Caplight tracks OncoC4, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OncoC4, Inc. worth (valuation)?
OncoC4, Inc.'s valuation is estimated at $660.0M based on funding round data.
Can I buy OncoC4, Inc. stock?
OncoC4, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OncoC4, Inc.'s last funding round?
OncoC4, Inc.'s most recent funding round was Series B on October 2, 2025.
Who are the main investors in OncoC4, Inc.?
Key investors in OncoC4, Inc. include Gobi Partners, Greater Bay Area Homeland.
Will OncoC4, Inc. IPO soon?
No public IPO plans have been announced for OncoC4, Inc..
How can I track OncoC4, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in OncoC4, Inc.'s shares on secondary markets.